Compare REFR & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFR | NTRB |
|---|---|---|
| Founded | 1965 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Industrial Specialties |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 57.0M |
| IPO Year | N/A | N/A |
| Metric | REFR | NTRB |
|---|---|---|
| Price | $1.14 | $4.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.1K | 16.7K |
| Earning Date | 03-05-2026 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,227,276.00 | ★ $2,278,321.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $0.93 | $4.17 |
| 52 Week High | $2.70 | $11.68 |
| Indicator | REFR | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 32.42 | 41.69 |
| Support Level | $1.14 | $4.51 |
| Resistance Level | $1.32 | $4.85 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 10.49 | 8.97 |
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.